AstraZeneca will purchase FibroGen China for about $160 million to gain rights to FibroGen's Roxadustat anemia drug in China, FibroGen said Thursday.
Roxadustat is indicated for anemia in chronic kidney disease. It has a pending regulatory decision for chemotherapy-induced anemia, FibroGen said.
FibroGen will be entitled to an enterprise value of $85 million and about $75 million in net cash held in China.
The transaction is expected to close by the middle of 2025.
Following closing, FibroGen will also repay its term loan facility to investment funds managed by Morgan Stanley Tactical Value.
The purchase comes as AstraZeneca is facing probes in China following investments in the country, Reuters reported separately.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。